RxDoctor Payments Data

Tiffany Graham

Optometrist · Warwick, RINPI 1043704794

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,204 of the $1,704 with a category attached, or 70.7%. 7 manufacturers reported payments, led by Coopervision Inc. at 31.1% of the total.

$1,704in general payments, 2019–2025

Across 37 payments — averaging $46.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$529
  • Oyster Point Pharma, Inc.$321
  • Alcon$244
  • Tarsus Pharmaceuticals, Inc.$191
  • Bausch & Lomb Americas Inc.$182
  • Novartis$153
  • plus $84 from 1 others

What the payments were for

  • Speaking & faculty fees$50029%
  • Food & beverage$1,20471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,704 in reported general payments places this provider in the 75th percentile of 226 optometrist providers in Rhode Island.

See all optometrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$37,227
Medicare patients
220
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$28,175
Latanoprost101$1,644
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$1,134
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha39$448
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$407
Timolol Maleate32$362
Brimonidine Tartrate23$318
Dorzolamide Hcl13$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$84$28,17534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 226 optometrist providers in Rhode Island.

Other optometrist in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →